Friday, 20 Oct 2017

You are here

The RheumNow Week in Review – 24 February 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

  1. Study of >43K Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis patients show a 14-34% increase risk for depression; but not for suicide or suicidal ideation. http://buff.ly/2lBwMb2
  2. Scleroderma Renal Crisis Criteria include HTN, Acute Kidney Injury, encephalopathy, seizures, microangiopathic hemolytic anemia https://t.co/J957AxYYGX
  3. 183 SLE Patients in a Phase II trial showed no benefit with IL-6 inhibition(PF-04236921) for 6 mos. The highest dose was D/C for safety. https://t.co/PdAZ0Petxs
  4. #RWCS17 Dr Bergman shows incredibly poor adherence to drug therapy. Suggests you need time and a plan to combat https://t.co/mLUzlsqUet
  5. Analysis 26 studies failed to show any predictors of mycohenolate mofetil responses in Lupus. More research needed. https://t.co/HwjhoLTS5
  6. Metanalysis shows no Cancer risk with Inflx (OR 1.68), ETN (0.79), ADA (0.93), ABA (1.04), RTX (0.58), TCZ (0.60), Tofa (1.15) https://t.co/TQp4AOAmuL
  7. Prior Authorizations is a problem for GI docs too - 63% use >25% FTE to do PA and 73% make > 5 calls (37% >10 calls) per day to payors https://t.co/yYSjjcTGwq
  8. CDC reports seasonal Influenza peaked in 2nd week Feb 2017 & will continue for weeks. No antiviral resistance seen thus far. https://t.co/YNMHbdYz1c
  9. Dr Mahadevan #RWCS17 shows data that there is a 1/2000 risk of bone fractures with chronic PPI use https://t.co/hYYWmPD6rE
  10. Dr Mahadevan #RWCS17 shows that PPI chronic use yields a 1/4000 risk of PPI induced C. ridicule diarrhea https://t.co/zIpl8k8DR0
  11. #rwcs2017 Dr Kavanaugh shows RCT where apemilast does well against etanercept in psoriasis. https://t.co/ZQYTdLBLZ9
  12. Dr Kevin Winthrop at #RWCS2017 reviews DMARD/Biologic effects on vaccine responses. Most effected by RTX, least by MTX. https://t.co/un74cCDo04
  13. ORAL strategy trial shows Xeljanz +MTX = Humira +MTX; but was inferior as monoRx Xeljanz in 1152 RA pts over 12 mos https://t.co/hb6RdEnWj6
  14. FDA approves the IL-17 inhibitor “Siliq” (brodalumab; from Valeant) for moderate-severe plaque psoriasis.Comes with a black box warning for suicide. https://t.co/rzSOVP1gd3
  15. Baricitinib (trade name “Olumiant” ) approved by EMA for use in EU for moderate-to-severe RA as monotherapy or combo with MTX. https://t.co/7lFqrfL3fF
  16. Higher Hip and Knee Replacement Revision Rates in Younger Patients 
  17. Sirukumab shows moderate efficacy in Rheumatoid Arthritis
  18. Abatacept shows modest efficacy in Giant Cell Arteritis
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review - 20 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses presentations from APLAR 2017 in Dubai, Catastrophic APS, safety of low-dose prednisone, frequency of psoriatic arthritis and a new drug for PsA and a hepatitis A outbreak in San Diego.

13 October 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!

The Big Need - NPs and PAs

Despite being one of the most satisfying of medical subspecialties, the number of U.S. rheumatologists is about to sharply decline.  These data were presented at the 2016 ACR meeting, where it was shown that the estimated total number of U.S. rheumatologists in in 2015 was 4,933 and is projected decrease to 3,645 by 2025. During this declining clinical supply, there will be a 138% increase in demand from 6,155 to 8,184 by 2030.

Arthritis Burden over $303 Billion Annually in U.S.

Arthritis of all types in the U.S. carried an economic burden of $303.5 billion in 2013, nearly 1% of the gross domestic product that year, according to a CDC analysis.

The RheumNow Week in Review - 6 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.